The stock price of Verona Pharma Plc ADR (NASDAQ: VRNA) has surged by 2.32 when compared to previous closing price of 63.31, but the company has seen a 11.11% gain in its stock price over the last five trading sessions. seekingalpha.com reported 2025-04-07 that Ohtuvayre’s robust launch for COPD treatment exceeded expectations, with Q4 revenue of $36.6 million and FY24 revenue of $42.3 million, indicating strong market demand. Verona’s financial health is solid with $399.757 million in cash, providing a cash runway into 2028, despite a net loss of $33.8 million in Q4. Verona is extending Ohtuvayre’s life cycle through new formulations and fixed-dose combinations, aiming for cash flow break-even with a quarterly run rate near $300 million.
Is It Worth Investing in Verona Pharma Plc ADR (NASDAQ: VRNA) Right Now?
The 36-month beta value for VRNA is at 0.24. Analysts have varying views on the stock, with 6 analysts rating it as a “buy,” 3 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for VRNA is 74.18M, and currently, shorts hold a 12.30% of that float. The average trading volume for VRNA on April 25, 2025 was 1.37M shares.
VRNA’s Market Performance
VRNA stock saw a decrease of 11.11% in the past week, with a monthly decline of -2.12% and a quarterly a decrease of 19.79%. The volatility ratio for the week is 4.56%, and the volatility levels for the last 30 days are 7.29% for Verona Pharma Plc ADR (VRNA). The simple moving average for the past 20 days is 9.50% for VRNA’s stock, with a 52.79% simple moving average for the past 200 days.
Analysts’ Opinion of VRNA
Many brokerage firms have already submitted their reports for VRNA stocks, with Cantor Fitzgerald repeating the rating for VRNA by listing it as a “Overweight.” The predicted price for VRNA in the upcoming period, according to Cantor Fitzgerald is $80 based on the research report published on April 21, 2025 of the current year 2025.
ROTH MKM, on the other hand, stated in their research note that they expect to see VRNA reach a price target of $68. The rating they have provided for VRNA stocks is “Buy” according to the report published on January 10th, 2025.
Wells Fargo gave a rating of “Overweight” to VRNA, setting the target price at $50 in the report published on October 03rd of the previous year.
VRNA Trading at 3.27% from the 50-Day Moving Average
After a stumble in the market that brought VRNA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -7.98% of loss for the given period.
Volatility was left at 7.29%, however, over the last 30 days, the volatility rate increased by 4.56%, as shares surge +0.93% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +9.19% upper at present.
During the last 5 trading sessions, VRNA rose by +11.11%, which changed the moving average for the period of 200-days by +280.83% in comparison to the 20-day moving average, which settled at $59.16. In addition, Verona Pharma Plc ADR saw 39.49% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at VRNA starting from Rickard Kathleen A., who sale 79,264 shares at the price of $8.35 back on Mar 12 ’25. After this action, Rickard Kathleen A. now owns 2,608,976 shares of Verona Pharma Plc ADR, valued at $661,942 using the latest closing price.
KATHLEEN RICKARD, the Officer of Verona Pharma Plc ADR, proposed sale 9,908 shares at $62.70 during a trade that took place back on Mar 12 ’25, which means that KATHLEEN RICKARD is holding shares at $621,232 based on the most recent closing price.
Stock Fundamentals for VRNA
Current profitability levels for the company are sitting at:
- -3.66 for the present operating margin
- 0.93 for the gross margin
The net margin for Verona Pharma Plc ADR stands at -4.1. The total capital return value is set at -0.36. Equity return is now at value -76.51, with -44.38 for asset returns.
Based on Verona Pharma Plc ADR (VRNA), the company’s capital structure generated 0.37 points at debt to capital in total, while cash flow to debt ratio is standing at -1.0. The debt to equity ratio resting at 0.6. The interest coverage ratio of the stock is -6.57.
Currently, EBITDA for the company is -138.53 million with net debt to EBITDA at 2.2. When we switch over and look at the enterprise to sales, we see a ratio of 123.11. The receivables turnover for the company is 1.13for trailing twelve months and the total asset turnover is 0.09. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.63.
Conclusion
In conclusion, Verona Pharma Plc ADR (VRNA) has had a better performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It is worth mentioning that the stock is currently trading in close proximity to its 50-day moving average and its 52-week high.
